Symbols / PPBT Stock $4.54 -0.22% Purple Biotech Ltd

Healthcare • Biotechnology • Israel • NCM
PPBT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Gil Efron CPA, M.A.
Exch · Country NCM · Israel
Market Cap 6.94M
Enterprise Value 8.43B
Income -26.39M
Sales —
FCF (ttm) -54.00K
Book/sh 0.01
Cash/sh 0.01
Employees 10
Insider 10d —
IPO Nov 20, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.09
PEG —
P/S —
P/B 907.98
P/C —
EV/EBITDA -1,208.93
EV/Sales —
Quick Ratio 1.24
Current Ratio 1.27
Debt/Eq 2.53
LT Debt/Eq —
EPS (ttm) -54.00
EPS next Y -0.64
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-13
Earnings (prior) 2026-03-13
ROA -15.97%
ROE -124.46%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 929.46K
Shs Float 1.84B
Insider Own 6.51%
Instit Own 13.12%
Short Float 0.86%
Short Ratio 0.75
Short Interest 7.97K
52W High 29.00
vs 52W High -84.35%
52W Low 3.60
vs 52W Low 26.11%
Beta -0.70
Impl. Vol. 41.92%
Rel Volume 0.26
Avg Volume 14.39K
Volume 3.70K
Target (mean) $30.00
Tgt Median $30.00
Tgt Low $30.00
Tgt High $30.00
# Analysts 1
Recom None
Prev Close $4.55
Price $4.54
Change -0.22%
About

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$30.00
Mean price target
2. Current target
$4.54
Latest analyst target
3. DCF / Fair value
$-1.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.54
Low
$30.00
High
$30.00
Mean
$30.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-13 main HC Wainwright & Co. Buy → Buy $30
2024-11-15 reit HC Wainwright & Co. Buy → Buy $33
2024-09-20 main HC Wainwright & Co. Buy → Buy $33
2024-08-19 main HC Wainwright & Co. Buy → Buy $8
2024-07-11 reit HC Wainwright & Co. Buy → Buy $10
2024-05-21 reit HC Wainwright & Co. Buy → Buy $10
2024-04-26 reit HC Wainwright & Co. Buy → Buy $10
2024-03-07 main Chardan Capital Buy → Buy $11
2024-03-05 reit HC Wainwright & Co. Buy → Buy $10
2024-02-27 reit HC Wainwright & Co. Buy → Buy $10
2023-11-21 main HC Wainwright & Co. Buy → Buy $10
2023-08-31 main HC Wainwright & Co. Buy → Buy $9
2023-08-30 main HC Wainwright & Co. Buy → Buy $9
2023-07-21 init JonesTrading — → Buy $8
2023-05-17 reit HC Wainwright & Co. Buy → Buy $7
2023-05-17 reit Chardan Capital Buy → Buy $11
2023-02-09 reit HC Wainwright & Co. — → Buy $7
2023-02-09 reit Chardan Capital — → Buy $11
2022-10-17 init HC Wainwright & Co. — → Buy $7
2022-09-08 init Chardan Capital — → Buy $11
News
RSS: Latest PPBT news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
6.98
-35.43%
10.80
-51.49%
22.27
-1.47%
22.60
Research And Development
3.73
-51.04%
7.62
-55.27%
17.03
+4.38%
16.32
Selling General And Administration
2.98
+1.64%
2.94
-39.41%
4.84
-18.75%
5.96
General And Administrative Expense
2.98
+1.64%
2.94
-39.41%
4.84
-18.75%
5.96
Salaries And Wages
1.74
-13.88%
2.02
-45.40%
3.69
-20.41%
4.64
Other Gand A
1.25
+35.73%
0.92
-20.17%
1.15
-12.94%
1.32
Other Operating Expenses
0.06
-4.84%
0.06
-68.37%
0.20
+63.33%
0.12
Total Expenses
6.98
-35.43%
10.80
-51.49%
22.27
-1.47%
22.60
Operating Income
-6.98
+35.43%
-10.80
+51.49%
-22.27
+1.47%
-22.60
Total Operating Income As Reported
-27.46
-149.50%
-11.01
+50.59%
-22.27
+1.47%
-22.60
EBITDA
-26.25
-272.23%
-7.05
+64.25%
-19.72
+8.23%
-21.49
Normalized EBITDA
-7.49
+30.62%
-10.79
+54.53%
-23.73
-8.84%
-21.80
Reconciled Depreciation
0.20
+9.14%
0.19
-5.58%
0.20
-1.99%
0.20
EBIT
-26.45
-265.47%
-7.24
+63.67%
-19.92
+8.17%
-21.69
Total Unusual Items
-18.77
-602.28%
3.74
-6.62%
4.00
+1203.26%
0.31
Total Unusual Items Excluding Goodwill
-18.77
-602.28%
3.74
-6.62%
4.00
+1203.26%
0.31
Special Income Charges
-20.48
-10039.60%
-0.20
0.00
0.00
Write Off
20.48
+10039.60%
0.20
0.00
0.00
Net Income
-26.39
-264.45%
-7.24
+63.58%
-19.88
+8.25%
-21.67
Pretax Income
-26.49
-263.95%
-7.28
+63.56%
-19.98
+8.19%
-21.76
Net Non Operating Interest Income Expense
-0.75
-254.25%
-0.21
+87.58%
-1.71
-418.47%
0.54
Interest Expense Non Operating
0.04
-4.88%
0.04
-26.79%
0.06
-16.42%
0.07
Net Interest Income
-0.75
-254.25%
-0.21
+87.58%
-1.71
-418.47%
0.54
Interest Expense
0.04
-4.88%
0.04
-26.79%
0.06
-16.42%
0.07
Interest Income Non Operating
0.23
-12.69%
0.26
-45.15%
0.47
-10.90%
0.53
Interest Income
0.23
-12.69%
0.26
-45.15%
0.47
-10.90%
0.53
Other Income Expense
-18.77
-602.28%
3.74
-6.62%
4.00
+1203.26%
0.31
Gain On Sale Of Security
1.72
-56.40%
3.94
-1.57%
4.00
+1203.26%
0.31
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-26.49
-263.95%
-7.28
+63.56%
-19.98
+8.19%
-21.76
Net Income From Continuing Operation Net Minority Interest
-26.39
-264.45%
-7.24
+63.58%
-19.88
+8.25%
-21.67
Net Income From Continuing And Discontinued Operation
-26.39
-264.45%
-7.24
+63.58%
-19.88
+8.25%
-21.67
Net Income Continuous Operations
-26.49
-263.95%
-7.28
+63.56%
-19.98
+8.19%
-21.76
Net Income Discontinuous Operations
—
—
0.00
0.00
Minority Interests
0.11
+171.79%
0.04
-59.79%
0.10
+5.43%
0.09
Normalized Income
-7.62
+30.57%
-10.98
+54.04%
-23.88
-8.67%
-21.98
Net Income Common Stockholders
-26.39
-264.45%
-7.24
+63.58%
-19.88
+8.25%
-21.67
Diluted EPS
1,099.20
+2589.24%
-44.16
-396.16%
-8.90
+96.29%
-240.00
Basic EPS
1,099.20
+2589.24%
-44.16
-396.16%
-8.90
+96.29%
-240.00
Basic Average Shares
0.02
-85.36%
0.16
-92.59%
2.21
+2348.24%
0.09
Diluted Average Shares
0.02
-85.36%
0.16
-92.59%
2.21
+2348.24%
0.09
Diluted NI Availto Com Stockholders
-26.39
-264.45%
-7.24
+63.58%
-19.88
+8.25%
-21.67
Depreciation Amortization Depletion Income Statement
0.20
+9.14%
0.19
-5.58%
0.20
-1.99%
0.20
Depreciation And Amortization In Income Statement
0.20
+9.14%
0.19
-5.58%
0.20
-1.99%
0.20
Depreciation Income Statement
0.20
+9.14%
0.19
-5.58%
0.20
-1.99%
0.20
Total Other Finance Cost
0.94
+117.87%
0.43
-79.72%
2.12
+3092.96%
-0.07
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
17.57
-52.56%
37.04
-16.40%
44.30
-18.89%
54.62
Current Assets
9.87
+10.75%
8.91
-43.58%
15.79
-52.53%
33.26
Cash Cash Equivalents And Short Term Investments
9.57
+12.32%
8.52
-44.69%
15.41
-52.01%
32.11
Cash And Cash Equivalents
8.72
+17.78%
7.40
-48.92%
14.49
-3.60%
15.03
Cash Financial
—
—
14.49
-3.60%
15.03
Other Short Term Investments
0.86
-23.69%
1.12
+21.67%
0.92
-94.60%
17.08
Receivables
0.15
-43.64%
0.28
+34.15%
0.20
-79.44%
1.00
Other Receivables
0.15
-43.64%
0.28
+34.15%
0.20
-79.44%
1.00
Prepaid Assets
—
—
0.20
-79.44%
1.00
Other Current Assets
0.14
+25.69%
0.11
-36.26%
0.17
+17.12%
0.15
Total Non Current Assets
7.71
-72.61%
28.13
-1.35%
28.51
+33.46%
21.37
Net PPE
0.35
+20.14%
0.29
-38.72%
0.47
-31.09%
0.68
Gross PPE
0.35
+20.14%
0.29
-38.72%
0.47
-31.09%
0.68
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.22
+35.37%
0.16
-48.10%
0.32
-32.33%
0.47
Other Properties
0.12
+0.00%
0.12
-19.48%
0.15
-28.37%
0.21
Goodwill And Other Intangible Assets
7.36
-73.57%
27.84
-0.72%
28.04
+35.58%
20.68
Other Intangible Assets
7.36
-73.57%
27.84
-0.72%
28.04
—
Investments And Advances
—
—
—
0.00
Other Investments
—
—
—
0.00
Non Current Prepaid Assets
—
—
—
0.00
Total Liabilities Net Minority Interest
7.91
+91.74%
4.13
-58.75%
10.01
+32.97%
7.52
Current Liabilities
7.75
+94.46%
3.99
-58.90%
9.70
+37.45%
7.06
Payables And Accrued Expenses
3.44
+29.68%
2.65
-62.04%
7.00
+1.91%
6.86
Payables
2.42
+31.46%
1.84
-56.31%
4.21
+48.59%
2.83
Accounts Payable
2.07
+42.27%
1.46
-58.81%
3.53
+65.67%
2.13
Other Payable
0.02
-69.23%
0.07
+22.64%
0.05
-41.76%
0.09
Current Accrued Expenses
1.03
+25.67%
0.82
-70.68%
2.79
-30.84%
4.03
Employee Benefits
0.16
+14.29%
0.14
-0.71%
0.14
-2.76%
0.14
Current Debt And Capital Lease Obligation
0.24
+33.33%
0.18
-2.66%
0.19
-3.09%
0.19
Current Capital Lease Obligation
0.24
+33.33%
0.18
-2.66%
0.19
-3.09%
0.19
Other Current Liabilities
4.07
+253.87%
1.15
-54.37%
2.52
—
Total Non Current Liabilities Net Minority Interest
0.16
+14.29%
0.14
-53.95%
0.30
-34.76%
0.47
Long Term Debt And Capital Lease Obligation
—
0.00
-100.00%
0.16
-49.22%
0.32
Long Term Capital Lease Obligation
—
0.00
-100.00%
0.16
-49.22%
0.32
Non Current Pension And Other Postretirement Benefit Plans
0.16
+14.29%
0.14
-0.71%
0.14
-2.76%
0.14
Stockholders Equity
9.71
-70.44%
32.86
-3.94%
34.21
-27.08%
46.91
Common Stock Equity
9.71
-70.44%
32.86
-3.94%
34.21
-27.08%
46.91
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Share Issued
1,858.91
+259.47%
517.13
+104.90%
252.38
+36.56%
184.82
Ordinary Shares Number
1,858.91
+259.47%
517.13
+104.90%
252.38
+36.56%
184.82
Treasury Shares Number
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Additional Paid In Capital
152.48
+3.29%
147.63
+10.85%
133.18
+5.36%
126.41
Retained Earnings
-171.08
-18.24%
-144.69
-5.27%
-137.45
-16.91%
-117.57
Gains Losses Not Affecting Retained Earnings
-0.10
+0.00%
-0.10
-24.05%
-0.08
+24.04%
-0.10
Minority Interest
-0.06
-207.84%
0.05
-43.33%
0.09
-51.87%
0.19
Other Equity Adjustments
-0.10
+0.00%
-0.10
-24.05%
-0.08
+24.04%
-0.10
Total Equity Gross Minority Interest
9.66
-70.65%
32.91
-4.04%
34.30
-27.18%
47.10
Total Capitalization
9.71
-70.44%
32.86
-3.94%
34.21
-27.08%
46.91
Working Capital
2.11
-57.06%
4.92
-19.16%
6.09
-76.77%
26.20
Invested Capital
9.71
-70.44%
32.86
-3.94%
34.21
-27.08%
46.91
Total Debt
0.24
+33.33%
0.18
-47.86%
0.35
-31.84%
0.52
Capital Lease Obligations
0.24
+33.33%
0.18
-47.86%
0.35
-31.84%
0.52
Net Tangible Assets
2.35
-53.09%
5.02
-18.58%
6.16
-76.50%
26.23
Tangible Book Value
2.35
-53.09%
5.02
-18.58%
6.16
-76.50%
26.23
Derivative Product Liabilities
—
—
2.52
0.00
Dueto Related Parties Current
0.33
+2.52%
0.32
-48.87%
0.62
+2.14%
0.61
Other Equity Interest
28.41
-5.37%
30.02
-22.14%
38.55
+0.98%
38.18
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.66
+60.63%
-14.37
+27.89%
-19.93
-19.06%
-16.73
Cash Flow From Continuing Operating Activities
-5.66
+60.63%
-14.37
+27.89%
-19.93
-19.06%
-16.73
Cash From Discontinued Operating Activities
—
—
0.00
0.00
Net Income From Continuing Operations
-26.49
-263.95%
-7.28
+63.56%
-19.98
+8.19%
-21.76
Depreciation Amortization Depletion
0.20
+9.14%
0.19
-5.58%
0.20
-1.99%
0.20
Depreciation
0.20
+9.14%
0.19
-5.58%
0.20
-1.99%
0.20
Depreciation And Amortization
0.20
+9.14%
0.19
-5.58%
0.20
-1.99%
0.20
Other Non Cash Items
-0.97
+74.07%
-3.73
-62.42%
-2.29
-172.12%
-0.84
Stock Based Compensation
0.31
-46.91%
0.58
-68.96%
1.88
-22.26%
2.41
Asset Impairment Charge
20.48
+10039.60%
0.20
0.00
0.00
Change In Working Capital
0.81
+118.65%
-4.33
-1681.02%
0.27
-91.58%
3.25
Change In Receivables
—
—
—
0.31
Changes In Account Receivables
—
—
—
0.31
Change In Payables And Accrued Expense
0.66
+114.79%
-4.43
-1816.28%
0.26
-91.20%
2.93
Change In Payable
0.66
+114.79%
-4.43
-1816.28%
0.26
-91.20%
2.93
Change In Account Payable
0.45
+121.68%
-2.08
-255.62%
1.33
+66.96%
0.80
Change In Other Working Capital
—
—
-0.16
-1572.73%
0.01
Change In Other Current Assets
0.15
+59.38%
0.10
-46.07%
0.18
-43.13%
0.31
Investing Cash Flow
0.63
+24.17%
0.51
-96.33%
13.88
-30.30%
19.91
Cash Flow From Continuing Investing Activities
0.63
+24.17%
0.51
-96.33%
13.88
-30.30%
19.91
Cash From Discontinued Investing Activities
—
—
—
0.00
Net PPE Purchase And Sale
-0.00
0.00
+100.00%
-0.00
+88.46%
-0.03
Purchase Of PPE
-0.00
0.00
+100.00%
-0.00
+88.46%
-0.03
Capital Expenditure
-0.00
—
-0.00
+98.68%
-0.23
Net Investment Purchase And Sale
0.45
+137.57%
0.19
-98.87%
16.68
-15.84%
19.82
Purchase Of Investment
-0.01
—
—
—
Sale Of Investment
0.46
+142.33%
0.19
-98.87%
16.68
-15.84%
19.82
Net Business Purchase And Sale
0.00
0.00
+100.00%
-3.55
0.00
Purchase Of Business
0.00
0.00
+100.00%
-3.55
0.00
Net Intangibles Purchase And Sale
—
0.00
0.00
+100.00%
-0.20
Purchase Of Intangibles
—
0.00
0.00
+100.00%
-0.20
Financing Cash Flow
6.33
-6.51%
6.77
+24.32%
5.45
+389.14%
1.11
Cash Flow From Continuing Financing Activities
6.33
-6.51%
6.77
+24.32%
5.45
+389.14%
1.11
Net Issuance Payments Of Debt
-0.22
-18.58%
-0.18
-8.93%
-0.17
-1.82%
-0.17
Repayment Of Debt
-0.22
-18.58%
-0.18
-8.93%
-0.17
-1.82%
-0.17
Long Term Debt Payments
-0.22
-18.58%
-0.18
-8.93%
-0.17
-1.82%
-0.17
Net Long Term Debt Issuance
-0.22
-18.58%
-0.18
-8.93%
-0.17
-1.82%
-0.17
Net Common Stock Issuance
3.15
-45.72%
5.81
+271.66%
1.56
+4.34%
1.50
Cash Dividends Paid
0.00
0.00
0.00
0.00
Proceeds From Stock Option Exercised
4.24
+109.07%
2.03
-59.44%
5.00
0.00
Net Other Financing Charges
-0.82
+1.91%
-0.84
+6.07%
-0.89
-485.53%
-0.15
Changes In Cash
1.31
+118.48%
-7.08
-1090.59%
-0.59
-113.86%
4.29
Effect Of Exchange Rate Changes
0.01
+275.00%
-0.00
-107.41%
0.05
+135.29%
-0.15
Beginning Cash Position
7.40
-48.92%
14.49
-3.60%
15.03
+38.02%
10.89
End Cash Position
8.72
+17.78%
7.40
-48.92%
14.49
-3.60%
15.03
Free Cash Flow
-5.66
+60.61%
-14.37
+27.91%
-19.93
-17.48%
-16.96
Common Stock Issuance
3.15
-45.72%
5.81
+271.66%
1.56
+4.34%
1.50
Interest Paid CFF
-0.02
+47.73%
-0.04
+21.43%
-0.06
+16.42%
-0.07
Interest Received CFI
0.19
-41.88%
0.32
-57.62%
0.76
+133.02%
0.32
Issuance Of Capital Stock
3.15
-45.72%
5.81
+271.66%
1.56
+4.34%
1.50
Sale Of Business
—
—
—
0.00
Cash Flow From Discontinued Operation
—
—
—
—
Cash From Discontinued Financing Activities
—
—
—
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category